title: Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule.
abstract: The in vitro human tumor colony-forming assay identified chloroquinoxaline sulfonamide (CQS) as an active agent at human plasma concentrations of > 100 micrograms/ml. In the initial phase I trial of CQS given every 28 days, peak plasma concentrations > 500 micrograms/ml were associated with reversible dose-limiting hypoglycemia and occasional cardiac arrhythmias. Therefore, we evaluated whether a weekly schedule of treatment might minimize the drug-associated toxicity while maintaining potential therapeutic concentrations. CQS was given intravenously over 1 h once per week for 4 weeks to 12 patients, beginning at a dose of 2,000 mg/m2. All patients underwent monitoring for cardiac arrhythmias and hypoglycemia. Plasma drug levels were measured following each dose. Mild hypoglycemia was the most common adverse effect. A median nadir plasma glucose concentration of 56 mg/dl was observed at a weekly dose of 2,500 mg/m2. Two patients experienced cardiac dysrhythmia while on study. Continuous electrocardiographic monitoring failed to identify any significant infusion-related arrhythmia. The median CQS plasma concentration measured 24 h following a 2,000-mg/m2 dose of CQS was > 100 micrograms/ml, and the cumulative area under the concentration x time curve (AUC) determined at concentrations of > or = 100 micrograms/ml was similar to that observed with the every-28-day schedule. The weekly schedule described herein appears to maximize the plasma AUC with an acceptable margin of safety. The recommended phase II dose and schedule for CQS is 2,000 mg/m2 given once per week. Although severe hypoglycemia is unlikely, glucose monitoring is appropriate for 6 h following CQS administration.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: J R
authors.initials: JR
authors.lastname: Rigas
authors.forename: P A
authors.initials: PA
authors.lastname: Francis
authors.forename: V A
authors.initials: VA
authors.lastname: Miller
authors.forename: W P
authors.initials: WP
authors.lastname: Tong
authors.forename: N
authors.initials: N
authors.lastname: Roistacher
authors.forename: M G
authors.initials: MG
authors.lastname: Kris
authors.forename: J P
authors.initials: JP
authors.lastname: Orazem
authors.forename: C W
authors.initials: CW
authors.lastname: Young
authors.forename: R P
authors.initials: RP
authors.lastname: Warrell
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D004334:Drug Administration Schedule; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D011810:Quinoxalines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D013424:Sulfanilamides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
chemical_list: D000970:Antineoplastic Agents; D011810:Quinoxalines; D013424:Sulfanilamides; C048021:5-chloroquinoxaline-2-sulfanilamide